Experimental & Molecular Medicine (EMM) Now Live - co-published with the Korean Society for Biochemistry and Molecular Biology (KSBMB), EMM seeks to highlight the improved clinical benefits for human health from experimental and translational research performed using specific molecular tools.
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market doi:10.1038/nbt0113-3 Pfizer's newly approved Xeljanz (tofacitinib) is poised to test the multibillion dollar rheumatoid arthritis market, currently dominated by tumor necrosis factor alpha inhibitors. Full Text
MEK inhibitor nears approval doi:10.1038/nbt0113-4 An FDA advisory committee has discussed materials on the MEK inhibitor trametinib, submitted by GlaxoSmithKline. Full Text
Anthrax drug first antibacterial mAb to win approval doi:10.1038/nbt0113-8 In mid-December, the FDA approved ABthrax, or raxibacumab, for use as an adjunct to conventional antibiotics in patients with inhalational anthrax. This approval is the first under the agency's 'animal rule'. Full Text
Cardiac stem cell therapies inch toward clinical litmus test doi:10.1038/nbt0113-5 Several upcoming phase 3 trials will deliver the data necessary to build a clear picture of the true potential of cell therapy in cardiac disease. Full Text
mAb about FGF21 doi:10.1038/scibx.2013.1 Amgen researchers have developed an antibody that mimics fibroblast growth factor 21 and has antidiabetic effects in monkeys. The findings are informing drug development by at least six companies. Full Text
Alzheimer's disease market: hope deferred doi:10.1038/nrd3922 The last few months have seen a flurry of trial results for investigational agents in Alzheimer's disease. This analysis investigates the different categories of developmental drugs, and provides an outlook to the future of the market. Full Text
Lung disorders: A new model and modulator of pulmonary oedema doi:10.1038/nrd3917 Two complementary studies have identified a new microdevice model — termed 'lung on a chip' — of pulmonary oedema, and identified a blocker of TRPV4 that inhibits pulmonary oedema in animal models. Full Text
Immunotherapy: Immunological bullets against Alzheimer's disease doi:10.1038/nrd3919 The exact contribution of innate immune signalling to Alzheimer's disease pathogenesis is still unclear. Now, researchers have identified IL-12 and IL-23 signalling as a therapeutic target in this neurodegenerative disorder. Full Text
Neurological disorders: Targeting translation in autism doi:10.1038/nrd3915 A study in Nature shows that pharmacological inhibition of eIF4E activity or siRNA-mediated knockdown of neuroligin 1 are novel potential targets for the treatment of Autism Spectrum Disorders. Full Text
Objective assessment of cancer genes for drug discovery doi:10.1038/nrd3913 This article describes and demonstrates an objective, systematic computational assessment of biological and chemical space. The approach can be applied to any human gene set to prioritize targets for further evaluation. Full Text
Kynurenines in the CNS: recent advances and new questions doi:10.1038/nrd3793 This Review describes the role of the kynurenine pathway in the pathology of Huntington's disease, migraine and multiple sclerosis, and highlights the most promising compounds that could be of therapeutic value. Full Text
Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance doi:10.1038/nm.3056 As expression of TRIP-Br2 is elevated in fat from obese humans, TRIP-Br2 might be a new therapeutic target against insulin resistance and hyperlipidemia. Full Text
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets doi:10.1038/nm.3048 The authors have engineered anti-BCL drugs to reduce platelet toxicity. Their compound is effective in several tumor models in vivo and had reduced toxicity in three patients with refractory leukemia. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment